Clinique Medico Chirurgicale Charcot

At Clinique Medico Chirurgicale Charcot investigators are exploring new treatment combinations for microsatellite stable (MSS) metastatic colorectal cancer that exhibits a high immune infiltrate. The goal is to improve survival outcomes by pairing standard chemotherapy with targeted immunotherapy, while also assessing the impact of circulating tumor DNA on adjuvant decisions.

• Combination chemotherapy (XELOX or FOLFOX) with bevacizumab
• Integration of pembrolizumab as an immunotherapy partner
• Biomarker-driven patient selection based on immune profile
• Use of circulating tumor DNA to guide adjuvant therapy

These studies aim to set new standards for managing digestive system cancers and to expand therapeutic options for patients with advanced disease.

The oncology department focuses on a range of breast cancer subtypes, including early triple-negative breast cancer, luminal A disease in post‑menopausal women, and high‑risk HR‑positive/HER2‑negative tumors in premenopausal patients. Research seeks to personalize therapy by reducing hormone treatment duration, evaluating pembrolizumab after strong neoadjuvant responses, and employing gene‑expression tools such as Prosigna® to guide chemotherapy decisions.

• Neoadjuvant chemo‑immunotherapy for triple‑negative disease
• Optimizing adjuvant aromatase inhibitor duration
• Gene‑expression profiling to decide on chemotherapy use
• Risk‑adapted strategies for young women with early breast cancer

By tailoring treatment intensity, the trials aim to maintain high cure rates while minimizing unnecessary side effects for women across different risk groups.

Across both digestive and breast oncology programs, the site is advancing the use of molecular markers. Trials incorporate circulating tumor DNA monitoring and gene expression (Prosigna®)-driven algorithms to personalize adjuvant therapy, striving for better disease‑free survival and more precise treatment allocation.

• ctDNA‑based decision making for adjuvant chemotherapy
• Implementation of Prosigna® assay in routine care
• Integration of molecular biomarkers into trial design
• Development of tailored therapeutic approaches across tumor types

These initiatives reflect a commitment to cutting‑edge diagnostics that can refine therapy choices for patients with cancer.